322. Hemophilia A and B: Clinical and Epidemiological: Poster III

Rates of inhibitor development and immune tolerance in children with severe Hemophilia A on emicizumab prophylaxis

Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran

Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering to mimic fitusiran

Immunogenicity assessment of concizumab in patients with Hemophilia A and b Assays developed to measure anti drug antibodies and integrated results from clinical trials

Quality of life and functional improvements with efanesoctocog alfa in patients with moderate to severe Hemophilia A A real world survey

Outcomes of marstacimab treatment in adolescent participants with Hemophilia A or B without inhibitors compared with prior routine prophylaxis Results from the phase 3 BASIS trial

Long term effect of marstacimab prophylaxis in hemophilia Α and Β on target joints Results from BASIS and OLE studies

Self reported prophylaxis treatment experience among persons living with hemophilia A in the US A cross sectional analysis of survey results combined with medical records

Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007

Exploratory analysis from HAVEN 1–4 to further contextualize injection site reactions among people with hemophilia A receiving emicizumab

Characterization of participants with elevated bleeding rates responding to prophylactic marstacimab treatment in the phase 3 BASIS trial